Catherine Seyler

Summary

Country: France

Publications

  1. pmc Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa
    Catherine Seyler
    INSERM U593, Universite Victor Segalen Bordeaux 2, 146 rue Leo Saignat, 33076 Bordeaux, France
    AIDS 21:1157-64. 2007
  2. doi request reprint Morbidity before and after HAART initiation in Sub-Saharan African HIV-infected adults: a recurrent event analysis
    Catherine Seyler
    Programme PAC CI, Abidjan, Cote d Ivoire
    AIDS Res Hum Retroviruses 23:1338-47. 2007
  3. pmc Anthropometric and immunological success of antiretroviral therapy and prediction of virological success in west African adults
    Eugene Messou
    Programme PAC, CI, Abidjan, Cote d Ivoire
    Bull World Health Organ 86:435-42. 2008
  4. ncbi request reprint Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Côte d'Ivoire
    Catherine Seyler
    Programme PAC CI, Abidjan, Cote d Ivoire
    Antivir Ther 8:385-93. 2003
  5. ncbi request reprint Risk factors for active tuberculosis after antiretroviral treatment initiation in Abidjan
    Catherine Seyler
    INSERM U593, Universite Victor Segalen Bordeaux 2, 146 rue Leo Saignat, 33076 Bordeaux, France
    Am J Respir Crit Care Med 172:123-7. 2005
  6. doi request reprint Rapid scaling-up of antiretroviral therapy in 10,000 adults in Côte d'Ivoire: 2-year outcomes and determinants
    Siaka Toure
    Aconda Association, Abidjan, Cote d Ivoire
    AIDS 22:873-82. 2008
  7. ncbi request reprint Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa
    Raoul Moh
    Trivacan ANRS 1269 study group, Abidjan, France
    AIDS 21:2483-91. 2007
  8. doi request reprint Occult HBV infection in untreated HIV-infected adults in Côte d'Ivoire
    Thérèse N'Dri-Yoman
    Programme PAC CI, Abidjan, Cote d Ivoire
    Antivir Ther 15:1029-34. 2010
  9. ncbi request reprint High incidence of atypical mycobacteriosis in African HIV-infected adults with low CD4 cell counts: a 6-year cohort study in Côte d'Ivoire
    Dominique Bonard
    Programme PAC CI, Abidjan, Cote d Ivoire, France
    AIDS 18:1961-4. 2004
  10. ncbi request reprint Incidence of neutropenia in HIV-infected African adults receiving co-trimoxazole prophylaxis: a 6-year cohort study in Abidjan, Côte d'Ivoire
    Siaka Toure
    Inserm Unité 593, Universite Victor Segalen Bordeaux 2, 146 rue Leo Saignat, 33076 Bordeaux Cedex, France
    Trans R Soc Trop Med Hyg 100:785-90. 2006

Collaborators

Detail Information

Publications23

  1. pmc Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa
    Catherine Seyler
    INSERM U593, Universite Victor Segalen Bordeaux 2, 146 rue Leo Saignat, 33076 Bordeaux, France
    AIDS 21:1157-64. 2007
    ..To analyse the association between the presence of resistance mutations and treatment outcomes. The impact of HIV-1 drug resistance mutations in African adults on HAART has so far never been reported...
  2. doi request reprint Morbidity before and after HAART initiation in Sub-Saharan African HIV-infected adults: a recurrent event analysis
    Catherine Seyler
    Programme PAC CI, Abidjan, Cote d Ivoire
    AIDS Res Hum Retroviruses 23:1338-47. 2007
    ..In HIV-infected patients on ART, the incidence of severe morbidity varied with the past history of morbidity. The past history of morbidity should be taken into account when comparing HIV morbidity rates before and after ART initiation...
  3. pmc Anthropometric and immunological success of antiretroviral therapy and prediction of virological success in west African adults
    Eugene Messou
    Programme PAC, CI, Abidjan, Cote d Ivoire
    Bull World Health Organ 86:435-42. 2008
    ..We assessed the gain or loss in body mass index (BMI), alone or in combination with the gain or loss in CD4+ T-cell count (CD4), as a tool for predicting the response to ART...
  4. ncbi request reprint Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Côte d'Ivoire
    Catherine Seyler
    Programme PAC CI, Abidjan, Cote d Ivoire
    Antivir Ther 8:385-93. 2003
    ..To evaluate survival, morbidity, and CD4 and viral load (VL) evolution in HIV-infected adults receiving antiretroviral therapy (ART) in Côte d'Ivoire...
  5. ncbi request reprint Risk factors for active tuberculosis after antiretroviral treatment initiation in Abidjan
    Catherine Seyler
    INSERM U593, Universite Victor Segalen Bordeaux 2, 146 rue Leo Saignat, 33076 Bordeaux, France
    Am J Respir Crit Care Med 172:123-7. 2005
    ....
  6. doi request reprint Rapid scaling-up of antiretroviral therapy in 10,000 adults in Côte d'Ivoire: 2-year outcomes and determinants
    Siaka Toure
    Aconda Association, Abidjan, Cote d Ivoire
    AIDS 22:873-82. 2008
    ..To assess the rates and determinants of mortality, loss to follow-up and immunological failure in a nongovernmental organization-implemented program of access to antiretroviral treatment in Côte d'Ivoire...
  7. ncbi request reprint Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa
    Raoul Moh
    Trivacan ANRS 1269 study group, Abidjan, France
    AIDS 21:2483-91. 2007
    ..To estimate the incidence and risk factors of mortality and severe morbidity during the first months following antiretroviral therapy (ART) initiation in West African adults...
  8. doi request reprint Occult HBV infection in untreated HIV-infected adults in Côte d'Ivoire
    Thérèse N'Dri-Yoman
    Programme PAC CI, Abidjan, Cote d Ivoire
    Antivir Ther 15:1029-34. 2010
    ..Here, we estimated the prevalence of untreated HIV-infected adults with negative serum HBsAg and detectable plasma HBV DNA in Côte d'Ivoire...
  9. ncbi request reprint High incidence of atypical mycobacteriosis in African HIV-infected adults with low CD4 cell counts: a 6-year cohort study in Côte d'Ivoire
    Dominique Bonard
    Programme PAC CI, Abidjan, Cote d Ivoire, France
    AIDS 18:1961-4. 2004
    ..In sub-Saharan Africa, where most patients start highly active antiretroviral therapy with low CD4 cell counts, improving the diagnosis of NTM may be relevant...
  10. ncbi request reprint Incidence of neutropenia in HIV-infected African adults receiving co-trimoxazole prophylaxis: a 6-year cohort study in Abidjan, Côte d'Ivoire
    Siaka Toure
    Inserm Unité 593, Universite Victor Segalen Bordeaux 2, 146 rue Leo Saignat, 33076 Bordeaux Cedex, France
    Trans R Soc Trop Med Hyg 100:785-90. 2006
    ..The consequences of associating co-trimoxazole with other haematotoxic drugs should be carefully assessed...
  11. doi request reprint Antiretroviral treatment changes in adults from Côte d'Ivoire: the roles of tuberculosis and pregnancy
    Eugene Messou
    INSERM U897, Universite Victor Segalen Bordeaux 2, Bordeaux, France
    AIDS 24:93-9. 2010
    ..To determine the rates and causes of first antiretroviral treatment changes in HIV-infected adults in Côte d'Ivoire...
  12. pmc Scaling up antiretroviral therapy in South Africa: the impact of speed on survival
    Rochelle P Walensky
    The Divisions of Infectious Disease, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
    J Infect Dis 197:1324-32. 2008
    ..Only 33% of eligible human immunodeficiency virus (HIV)-infected patients in South Africa receive antiretroviral therapy (ART). We sought to estimate the impact of alternative ART scale-up scenarios on patient outcomes from 2007-2012...
  13. doi request reprint Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration
    Paula Braitstein
    Department of Medicine, Indiana University, Indianapolis, Indiana, USA
    J Womens Health (Larchmt) 17:47-55. 2008
    ....
  14. pmc The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Côte d'Ivoire
    Elena Losina
    Department of Biostatistics and Epidemiology, Boston University School of Public Health, Boston, MA, USA
    Antivir Ther 12:543-51. 2007
    ..Studies in developed countries have shown highly active antiretroviral therapy (HAART) decreases incidence of severe opportunistic diseases (ODs) in HIV-infected patients beyond that which is expected from changes in CD4+ T-cell count...
  15. ncbi request reprint Pattern of bacterial diseases in a cohort of HIV-1 infected adults receiving cotrimoxazole prophylaxis in Abidjan, Côte d'Ivoire
    Xavier Anglaret
    INSERM U330, Universite Victor Segalen, Bordeaux, France
    AIDS 17:575-84. 2003
    ..WHO/UNAIDS recommended that cotrimoxazole should be prescribed in Africa in HIV-infected adults with CD4 cell counts < 500 x 10 /l, while closely monitoring bacterial diseases in as many settings as possible...
  16. ncbi request reprint Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries
    Paula Braitstein
    Lancet 367:817-24. 2006
    ..We compared baseline characteristics and outcomes during the first year of HAART between HIV-1-infected patients in low-income and high-income settings...
  17. ncbi request reprint Nonantiretroviral drug consumption by CD4 cell count in HIV-infected adults: a 5-year cohort study in Côte d'Ivoire
    Nohelly Nombela
    Unité INSERM U 593, Universite Victor Segalen, Bordeaux, Cedex, France
    J Acquir Immune Defic Syndr 41:225-31. 2006
    ..Meanwhile, they roughly suggest that successful antiretroviral treatment, which would stabilize the CD4 count above 500 cells/mm, could reduce by 5-fold the cost of nonantiretroviral drugs in HIV-infected adults in Abidjan...
  18. ncbi request reprint Cohort Profile: Antiretroviral Therapy in Lower Income Countries (ART-LINC): international collaboration of treatment cohorts
    Francois Dabis
    INSERM U 593, ISPED, Universite Victor Segalen, Bordeaux Cedex, France
    Int J Epidemiol 34:979-86. 2005
  19. ncbi request reprint Impact of vital status investigation procedures on estimates of survival in cohorts of HIV-infected patients from Sub-Saharan Africa
    Xavier Anglaret
    INSERM U 593, Universite Victor Segalen, Bordeaux, France
    J Acquir Immune Defic Syndr 35:320-3. 2004
    ..We suggest that the percentage of deaths known through VSIPs would be a useful indicator to be added when reporting survival data from urban HIV cohort studies in sub-Saharan Africa...
  20. ncbi request reprint Risk factors for active tuberculosis in adults on highly active antiretroviral therapy in Africa
    Catherine Seyler
    AIDS 20:1463; author reply 1463-5. 2006
  21. pmc Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings
    Graeme Meintjes
    Institute of Infectious Diseases and Molecular Medicine and Department of Medicine, University of Cape Town, Cape Town, South Africa
    Lancet Infect Dis 8:516-23. 2008
    ..It is envisaged that these definitions could be used by clinicians and researchers in a variety of settings to promote standardisation and comparability of data...
  22. ncbi request reprint Urinary pH in HIV-infected adults in Ivory Coast and in France
    Emmanuel Mortier
    AIDS 17:2003-5. 2003
  23. ncbi request reprint Are a past history of tuberculosis and WHO clinical stage associated with incident tuberculosis in adults receiving antiretroviral therapy?, reply to Lawn et al
    Eric Ouattara
    AIDS 21:389-90. 2007